Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Johnson & Johnson
(NY:
JNJ
)
161.99
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Johnson & Johnson
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
3 Safe Stocks with Safe Dividends for Your Portfolio
September 11, 2024
Secure your portfolio with stocks known for their stability and reliable dividend payouts, offering a sense of security during uncertain times.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Is Hims & Hers Health the Next Teladoc?
September 11, 2024
Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic.
Via
The Motley Fool
Exposures
COVID-19
2 Stocks That Are Passive Income Machines to Buy and Hold Forever
September 11, 2024
You can take these dividends straight to the bank.
Via
The Motley Fool
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
September 10, 2024
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential.
Via
Benzinga
Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
September 10, 2024
Kenvue Inc., owner of major brands like Tylenol, is poised for a technical knockout with a Golden Cross pattern and legal win.
Via
Benzinga
Analyzing NYSE:JNJ's Dividend Potential.
September 02, 2024
Why JOHNSON & JOHNSON (NYSE:JNJ) qualifies as a good dividend investing stock.
Via
Chartmill
Will JOHNSON & JOHNSON Break Out? A Technical Analysis Perspective.
August 30, 2024
A technical analysis of JOHNSON & JOHNSON (NYSE:JNJ) shows it may be setting up for a breakout.
Via
Chartmill
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
August 29, 2024
Via
Benzinga
Dell, CoStar, PayPal And A Major Health Care Stock On CNBC's 'Final Trades'
September 06, 2024
Bill Baruch of Blue Line Capital named Dell Technologies Inc. his "final trade" on CNBC's "Halftime Report."
Via
Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
September 06, 2024
Via
Benzinga
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
September 05, 2024
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson Raises Talc Settlement Offer to $9B, Moves Closer to Settlement Victory
September 05, 2024
Johnson & Johnson boosts talc settlement offer to $9 billion, gaining support from key lawyer Allen Smith for quicker claimant payouts.
Via
Benzinga
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
September 05, 2024
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
August 28, 2024
Via
Benzinga
2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem
September 05, 2024
Johnson & Johnson and Altria Group are two prominent dividend stocks, but I wouldn't rely on their payouts.
Via
The Motley Fool
Court Orders Johnson & Johnson To Compensate Auris Health Shareholders $1B
September 04, 2024
Johnson & Johnson is ordered to pay $1 billion in damages to Auris Health shareholders for breaching a 2019 merger agreement. The ruling finds Johnson & Johnson failed to support critical technology,...
Via
Benzinga
3 Dividend Stocks to Double Up on Right Now
September 04, 2024
These companies have excellent records of growing their dividends.
Via
The Motley Fool
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
September 03, 2024
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Critical Insights From Johnson & Johnson Analyst Ratings: What You Need To Know
September 03, 2024
Via
Benzinga
Is Johnson & Johnson the Best Dividend Stock for You?
September 01, 2024
You won't find a more dependable dividend payer on Wall Street. But whether it's the best stock for you depends on other factors.
Via
The Motley Fool
Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income.
September 01, 2024
Via
The Motley Fool
Johnson & Johnson-Spin Off Kenvue Wins Lawsuit Over Pain Killer Tylenol 'Rapid Release' Gelcaps
August 30, 2024
Kenvue defends against a consumer lawsuit alleging that its Tylenol "Rapid Release" gelcaps did not relieve pain faster than regular tablets. A federal judge ruled the claims were preempted by FDA...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Elliott Wave Technical Analysis: Johnson & Johnson - Friday, Aug. 30
August 30, 2024
JNJ appears to be in the latter stages of wave {iii} of 1.
Via
Talk Markets
Johnson & Johnson's Golden Cross: A Bullish Prescription For Investors?
August 29, 2024
Johnson & Johnson (NYSE:JNJ) achieves Golden Cross, signaling shift to bullish trend. Stock at $164.43, above all key moving averages & with positive catalysts ahead.
Via
Benzinga
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
August 29, 2024
Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows...
Via
Benzinga
Exposures
Product Safety
12 Dividend Stocks to Earn Income Every Month
August 28, 2024
Get paid a dividend on a monthly basis.
Via
The Motley Fool
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
August 27, 2024
There's no reason to succumb to gloom and doom here.
Via
The Motley Fool
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
August 27, 2024
Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatment. Addex could receive up to $330 million plus royalties under the...
Via
Benzinga
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
August 27, 2024
Cramer gives his take on E.l.f Beauty, Acadia Pharmaceuticals, B&G Foods, Lucid, SoFi, Dell, Johnson & Johnson, UWM and Symbotic.
Via
Benzinga
Here Are 2 Great Vanguard Dividend ETFs: Which Is Right For You?
August 27, 2024
Now could be a great time to buy excellent dividend stocks, but these two ETFs have different approaches.
Via
The Motley Fool
Topics
ETFs
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.